erlotinib hydrochloride has been researched along with gdc 0449 in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (gdc 0449) | Trials (gdc 0449) | Recent Studies (post-2010) (gdc 0449) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 666 | 68 | 611 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | gdc 0449 (IC50) |
|---|---|---|---|
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.02 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.02 | |
| Smoothened homolog | Mus musculus (house mouse) | 0.07 | |
| Sonic hedgehog protein | Homo sapiens (human) | 0.8825 | |
| Sonic hedgehog protein | Mus musculus (house mouse) | 0.0077 | |
| Smoothened homolog | Homo sapiens (human) | 0.0222 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, A; Bao, B; Gadgeel, SM; Ginnebaugh, KR; Li, Y; Maitah, MY; Sarkar, FH | 1 |
| Chasapi, V; Soura, E; Stratigos, AJ | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Allred, JB; Almada, LL; Bekaii-Saab, T; Borad, MJ; Bryce, AH; Callstrom, MR; Carr, RM; Colon-Otero, G; Erlichman, C; Fernandez-Zapico, ME; Grothey, A; Haluska, P; Hung, MC; Jatoi, A; Kim, GP; Lamberti, MJ; Lingle, WL; Lowe, VJ; Ma, WW; Marks, DL; McCleary-Wheeler, AL; McWilliams, RR; Molina, JR; Northfelt, DW; Okuno, SH; Palmer, SR; Pitot, HC; Qi, Y; Smyrk, TC; Tolosa, EJ | 1 |
| Dorna, D; Frąckowiak, M; Kleszcz, R; Paluszczak, J | 1 |
2 review(s) available for erlotinib hydrochloride and gdc 0449
| Article | Year |
|---|---|
Pharmacologic treatment options for advanced epithelial skin cancer.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome | 2015 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
1 trial(s) available for erlotinib hydrochloride and gdc 0449
| Article | Year |
|---|---|
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridines | 2020 |
2 other study(ies) available for erlotinib hydrochloride and gdc 0449
| Article | Year |
|---|---|
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Hedgehog Proteins; Humans; Lung Neoplasms; MicroRNAs; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Hedgehog Proteins; Humans; Phosphatidylinositol 3-Kinases; Squamous Cell Carcinoma of Head and Neck; Wnt Signaling Pathway | 2023 |